Single-cell analysis reveals EP4 as a target for restoring T cell infiltration and sensitizing prostate cancer to immunotherapy.
Shihong PengPan HuYu-Tian XiaoWeiqiang LuDandan GuoShixiu HuJiayi XieMinna WangWeiwei YuJun-Jie YangHuang ChenXiaomin ZhangYasheng ZhuYe WangYue YangGuanghui ZhuSujun ChenJian WangBo ZhangWeidong ChenHuangan WuZhenliang SunTao DingHankun ZhangZhengfang YiMingyao LiuShancheng RenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our study identified EP4 as a specific target for prostate cancer immunotherapy and demonstrated that YY001 inhibited the growth of prostate tumors by regulating the immune microenvironment and strongly synergized with anti-PD-1 antibodies to convert completely unresponsive prostate cancers into responsive cancers, resulting in marked tumor regression, long-term survival, and lasting immunologic memory.